Cybin announces positive topline data from phase 1 studies of proprietary deuterated dmt molecules cyb004 and spl028

Toronto--(business wire)--cybin inc. (nyse american:cybn) (neo:cybn) (“cybin” or the “company”), a clinical-stage biopharmaceutical company committed to revolutionizing mental healthcare by developing new and innovative psychedelic-based treatment options, today announced positive safety, pharmacokinetic (“pk”) and pharmacodynamic (“pd”) data from its phase 1 studies of cyb004 (iv) and spl028 (iv and im) in healthy volunteers. cyb004 and spl028 are proprietary deuterated dmt molecules within th.
CYBN Ratings Summary
CYBN Quant Ranking